Related Experiment Video

Updated: Nov 19, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.0K

SOX9: An emerging driving factor from cancer progression to drug resistance

Munmun Panda1, Surya Kant Tripathi1, Bijesh K Biswal1

  • 1Cancer Drug Resistance Laboratory, Department of Life Science, National Institute of Technology Rourkela, Odisha 769008, India.

Biochimica Et Biophysica Acta. Reviews on Cancer
|February 1, 2021
PubMed

Insights

SOX9, a key transcription factor, plays dual roles in cancer, influencing tumor progression, stemness, and drug resistance. Understanding its signaling network offers potential for novel anticancer drug development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Transcription factor dysregulation is central to cancer pathogenesis.
  • SOX9 is a critical transcription factor implicated in various cancers, acting as either a proto-oncogene or tumor suppressor.
  • SOX9 expression is modulated by epigenetic and post-translational modifications, including miRNAs, methylation, phosphorylation, and acetylation.

Purpose of the Study:

  • To review the biological implications of SOX9 in cancer progression and drug resistance.
  • To elucidate the SOX9 signaling network.
  • To identify SOX9 as a potential therapeutic target for novel anticancer drug design.

Main Methods:

  • Literature review of recent studies on SOX9 in cancer.
  • Analysis of SOX9's role in tumor microenvironment (TME) regulation.
  • Investigation of SOX9's involvement in cancer stem cell (CSC) and epithelial-mesenchymal transition (EMT) induction.

Main Results:

  • SOX9 significantly impacts cancer development, progression, and the TME.
  • SOX9 activation promotes stem cell features, driving EMT and contributing to cancer drug resistance.
  • Differential SOX9 expression may serve as a prognostic and progression biomarker.

Conclusions:

  • SOX9 is a multifaceted regulator in cancer, linked to progression, stemness, and drug resistance.
  • The SOX9 signaling network presents a promising target for developing new anticancer therapies.
  • Further research into SOX9's role can lead to improved cancer diagnostics and therapeutics.
Keywords:
CSCCancerDrug resistanceEMTSOX9Signaling

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.5K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.9K

Related Concept Videos

Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
42.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.3K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K